Tom Wiggans, Pardes Biosciences CEO
Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial
A next-gen Covid-19 antiviral has flunked a Phase II test, forcing its developer to go into some serious soul searching.
The mid-stage readout was crucial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
